Brucella vaccine

Bang's Disease Vaccination Regulation

brucella abortus vaccine

traveler's diarrhea vaccine | travelers' diarrhea vaccine

First DTaP vaccination

Newcastle disease non-vaccinating status

grant a worldwide, exclusive, perpetual licence of GSK's Nimenrix vaccine for bacterial meningitis (serogroups A, C, W and Y), and divest GSK's Mencevax vaccine for bacterial meningitis (serogroups A, C, W and Y) worldwide, and enter into an exclusive distribution agreement for Germany and Italy, a 10 year supply agreement, and transfer marketing authorisations in the relevant countries for Novartis' TD-Pur and Dif-Tet-All vaccines for diphtheria and tetanus.

What have been the federal government's activities in the area of hepatitis B vaccination, specifically: (a) information learned by Health Protection Branch regulators from the decision by France to suspend the administration of the hepatitis B vaccination; (b) actions taken by Health Canada to assess safety of the vaccination B product and, in particular, to survey for adverse reactions over and above voluntary reporting; (c) information requested and received from international bodies such as the World Health Organization about the safety of the hepatitis B vaccination; (d) reassessment of existing evidence in the new drug submissio ...[+++]n for the hepatitis B vaccination previously assessed; and (e) evidence that plasma was not involved in any part of the manufacturing of the hepatitis B vaccination?

The additional money pledged will go towards vaccines for the two biggest childhood killers; pneumonia and diarrhoea, as well as for areas where vaccines are new or currently underused such as rubella, typhoid and meningitis.

Question No. 446 Ms. Kirsty Duncan: With respect to the current pandemic of new influenza A (H1N1): (a) what is the key leadership shown by the organizational reporting chart, from the two lead ministries, the Public Health Agency of Canada and Public Safety Canada, through to the deputy ministers; (b) what is the decision-making process to determine which of the two ministries leads on issues; (c) what, if any, funding requests have been made by government departments for pandemic planning since the beginning of the pandemic in Canada; (d) what, if any, additional funding is required to ensure all government departments have tested their H1N1 plans and rolled them out to their employees; (e) what, if any, specific agreements have been ...[+++]signed with the provinces and territories, and which, if any, agreements still need to be signed; (f) what are the government’s identified critical services, what is the decision-making process to reduce services if required, and who has responsibility for these decisions; (g) how will the government acquire and distribute medical countermeasures if required; (h) what guidance is being provided to foreign missions, including consulates, embassies, high commissions and trade offices, and what is the decision-making process to reduce services, or repatriate staff; (i) what guidance is being provided to the Canadian Forces, including the army, the air force and the navy, and what recommendations are being made for military personnel; (j) with regard to recommendations being made to the Canadian Forces and military personnel concerning vaccinations, what processes are in place to (i) re-evaluate policies as required, (ii) ensure legal compliance and respect ethical considerations, (iii) ensure protection of our troops in Afghanistan; (k) on what date was the pandemic vaccine ordered, and what, if any, effect did having only one supplier, or the decision to use adjuvant, had on the delivery date for the H1N1 vaccine; (l) what, i ...